Newsletter Signup | Join Community
mFOLFIRINOX improves the treatment of early stage surgically treated and advanced stage pancreatic cancer.
Stage III pancreatic cancer is treated with surgery, chemotherapy, or participation is a clinical trial.
ASCO 2019: PARP Inhibitors Benefit People with Pancreatic Cancer Who Have a BRCA Mutation
New pancreatic cancer treatments to be revealed at this ASCO this year.
U Penn doctors report combination immunotherapy with Opdivo, APX005M very active against pancreatic cancer.
Dr. James Moser, Ass Prof of Surgery Harvard Medical School - Co Director Pancreatic Inst, BIDMC
November is pancreatic cancer awareness month
MacCaskill to bring her inspirational story of survival to the Pancreatic and Cancer Connect Communities
Stay Current With Pancreatic Cancer Treatment Advances & Connect with Others
Surgery and systemic therapy is the primary treatment of stage I-II pancreatic cancer
When pancreatic cancer has returned following initial treatment, it is referred to as recurrent or relapsed cancer.
Learn about pancreatic cancer.
Diagnosed with Pancreatic Cancer: 10 Tips on How to Get The Most From Your Doctor
A diagnosis of diabetes may be added to the list of signs and symptoms resulting from pancreatic cancer.
What Are the Warning Signs of Pancreatic Cancer?
John Hopkins doctors update results on GVAX vaccine trial for pancreatic cancer
Onivyde Approved for Pancreatic Cancer
Clinical trial evaluating immunotherapy and chemotherapy in pancreatic cancer begins at leading cancer centers
MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I for Pancreatic Cancer
Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents
Research suggests a promising new way to screen for and detect early pancreatic cancer
In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival
Radioimmunotherapy and Gemcitabine Combination Shows Extended Survival Times for Metastatic Pancreatic
MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer.
Jakafi Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation
Positive Results from Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer
Alcohol Modestly Increases Risk of Pancreatic Cancer.
Relief for Side Effects to Skin for Patients Taking EGFR Inhibitors.
Abraxane Plus Gemzar Improves Survival in Metastatic Pancreatic Cancer
Obesity Increases Risk of Pancreatic Cancer
Blood Type Linked to Risk of Pancreatic Cancer
Obesity Worsens Outcomes After Surgery for Pancreatic Cancer.
Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survivals
Gemzar Versus 5-FU for Adjuvant Treatment of Pancreatic Cancer
Sutent and Afinitor Show Promise against Advanced Pancreatic Neuroendocrine Tumors
Aspirin Reduces Risk of Pancreatic Cancer
Heavy Drinking Increases Pancreatic Cancer Risk
Soda Consumption May Be Linked to Pancreatic Cancer
Tomudex® Plus Eloxatin® Effective in Gemzar®-Resistant Metastatic Pancreatic Cancer
Pancreatic cancer is one of the deadliest forms of cancer.
Radiation Therapy May Be Effective in Early Pancreatic Cancer.
Sutent® Provides Significant Benefit for Advanced Pancreatic Islet Cell Tumors: Clinical Trial Stopped Early
Addition of Avastin® to Gemzar® Does Not Improve Survival as Initial Therapy in Advanced Pancreatic Cancer.
Combination of Alimta® and Gemzar® Does Not Improve Pancreatic Cancer Survival
Type I Diabetes Associated with Increased Risk of Pancreatic Cancer
Cytokeratin 20 Expression Linked to Poor Survival in Pancreatic Cancer
Combination Chemotherapy in Addition to Gemzar® Improves Survival over Gemzar Alone in Advanced Pancreatic Cancer
Addition of Xeloda® to Gemzar® Improves Survival in Patients with Advanced Pancreatic Cancer and Good Performance Status
Vitamin D May Reduce the Risk of Pancreatic Cancer
Updates in the Management of Gastrointestinal Cancers: A Report from the 9th World Congress on Gastrointestinal Cancer
Gemzar® Delays Recurrences in Early Pancreatic Cancer
Elevated Pancreatic Cancer Risk Among First-Degree Relatives
HIFU Promising in Advanced Pancreatic Cancer
Processed Meat Associated with Increased Incidence of Pancreatic Cancer.
Colloidal Phosphorus-32 Combined with Radiation Therapy & 5-Fluorouracil Offers Promise Treatment for Pancreatic Cancer
High Serum Insulin and Insulin Resistance Increase Pancreatic Cancer Risk
Gene Expression Profiling Helps Distinguish Between Pancreatic Cancer and Benign Conditions
Long-Term Results Indicate that Adjuvant Chemotherapy Without Radiation Improves Survival in Pancreatic Cancer
Test Holds Promise for Early Detection of Pancreatic Cancer
Xeloda® Improves Survival with Pancreatic Cancer
Aspirin May Lower the Incidence of Pancreatic Cancer in Women
AMG 479 Produces Promising Results in Metastatic Pancreatic Cancer
New Vaccine Significantly Improves Survival in Patients with Pancreatic Cancer.
Addition of Axitinib Fails to Improve Pancreatic Cancer Outcomes
Addition of Tarceva™ to Gemzar® Improves Survival in Advanced Pancreatic Cancer
Processed Meat Linked with Increased Risk of Pancreatic Cancer
Gemzar® Improves Survival with Early Pancreatic Cancer
Dietary Folate Reduces Risk of Pancreatic Cancer in Male Smokers.
Recent-onset Diabetes Linked with Pancreatic Cancer
Snus Increases Risk of Pancreatic Cancer
Abraxane Approved for Metastatic Pancreatic Cancer.
More Extensive Chemotherapy Plus Radiation Therapy May Allow for Greater Surgical Removal of Pancreatic Cancer
Novel Chemotherapy Regimen for Locally Advanced Pancreatic Cancer.
Addition of Gemzar® to Adjuvant Therapy Improves Survival in Early Pancreatic Cancer.
Erbitux® Plus Gemzar® Looks Promising for Advanced Pancreatic Cancer
Aspirin—but not other types of non-steroidal anti-inflammatory drugs (NSAIDs)—may reduce the risk of pancreatic cancer.
Obesity Increases Pancreatic Cancer Risks
Pancreatic Cancer Care Is Inconsistent
Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen.
Addition of Gemzar® in Early Pancreatic Cancer May Modestly Improve Survival
Blood Type Gene Linked with Pancreatic Cancer Risk
Depression May Persist With Metastatic Cancer.
Levels of CA 19-9 Following Treatment Not Indicative of Survival in Pancreatic Cancer
Optical Markers Offer Promise for Earlier Detection of Pancreatic Cancer
Addition of Erbitux® Does Not Improve Outcomes in Pancreatic Cancer
Chemotherapy Improves Pancreatic Cancer Survival
Abraxane®/Gemzar® Promising in Pancreatic Cancer
Immunotherapy for Pancreatic Cancer Boosts Survival by More Than 75% in Mice; Trials in Humans Coming.
Flavonols May Reduce Risk of Pancreatic Cancer in Smokers
Minimally Invasive Laparoscopy May Be Used to Alleviate Stomach
Poor Oral Health Poses Increased Risk of Developing Pancreatic Cancer
Addition of Irinotecan to Gemzar® Does Not Improve Survival with Advanced Pancreatic Cancer
Addition of Eloxatin® or Platinol® to Gemzar® Improves Survival in Advanced Pancreatic Cancer.
Pancreatic Cancer Research Map Will Track Researchers, Studies and Funding Opportunities
FDA Approves Tarceva® in Combination with Gemzar® for Pancreatic Cancer
Adjuvant Chemotherapy Without Radiation Improves Survival in Pancreatic Cancer
Increased Dietary Folate Decreases Risk of Pancreatic Cancer.
CA19-9 Marker of Survival in Pancreatic Cancer
Rubitecan (Orathecin) Produces Responses in Refractory Pancreatic Cancer
Polychemotherapy for Advanced Pancreatic Cancer Improves Responses.
Talabostat plus Gemzar® Shows Potential in Treatment of Advanced Pancreatic Cancer
Vaccine May Extend Survival in Pancreatic Cancer
Survival with Pancreatic Cancer Varies by Number of Lymph Nodes Removed
Oncophage® may Improve Survival in Operable Pancreatic Cancer
Endoscopic Ultrasound Accurately Rules Out Pancreatic Cancer.
K-ras in Surgical Margins Associated with Worse Prognosis in Pancreatic Cancer
Marimastat a New Anticancer Drug for Advanced Pancreatic Cancer
Further Data Associating Being Overweight with Increased Risk of Pancreatic Cancer
Chronic Aspirin Use May Increase Risk of Pancreatic Cancer in Women
miRNA Expression Can Help Diagnose Pancreatic Cancer.
According to results published in the
Further Evidence that Rubitecan Offers Benefit for Refractory Pancreatic Cancer
Addition of Tarceva® to Gemzar® Improves Survival in Pancreatic Cancer.
Cancer Surgery-Related Death Rates Are Lower in Hospitals that Treat More Patients
Initial Surgery to Connect the Stomach with the Jejunum May Prevent Obstruction of the Stomach with Pancreatic Cancer
Surgeon Volume Directly Related to Surgical Outcomes
EndoTAG™-1 Shows Promise in Treatment of Pancreatic Cancer
Surgery Underused for Early Pancreatic Cancer.
Ultrasound-Guided Injections of Biological Therapy Feasible in Locally Advanced Pancreatic Cancer
Neoadjuvant Radiation Improves Survival in Pancreatic Cancer
Surgery and systemic therapy is primary treatment of stage III ovarian cancer
Different Chemotherapy Combinations Effective in Pancreatic Cancer
GEMOX Active in Recurrent Pancreatic Cancer
Gemzar® plus Second Chemotherapy Agent Provides Small Survival Benefits in Advanced Pancreatic Cancer
Dr. Skip Burris explains targeted therapies.
Gemzar plus Avastin Does Not Improve Survival in Advanced Pancreatic Cancer
Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk.
Surgery for Pancreatic Cancer: Removing Additional Lymph Nodes Appears Not to Improve Survival.
NCCN Updates Pancreatic Cancer Guidelines
Lynch Syndrome Increases Risk of Pancreatic Cancer
Updates on the Management of Advanced Hepato-pancreato-biliary Malignancies
Photodynamic Therapy Effective for Some Inoperable Pancreatic Cancer
Abraxane Improves Survival in Pancreatic Cancer
Chemotherapy and Radiation Therapy Prolong Survival and Improve Quality of Life
First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study
Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer
Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer